Cannabis and cannabinoids are increasingly used for treating mental problem

5 Strategies to Win at Retail with Cannabis

5 Strategies to Win at Retail with Cannabis

The paper, printed Monday in The Lancet Psychiatry, checked out 83 earlier research carried out over almost 4 a long time on medical cannabinoids, together with merchandise from the hashish plant, reminiscent of leaves, buds and oils. The researchers in their trial on 3,000 people, examined the effect of medicinal cannabinoids in patients with depression, anxiety, attention-deficit hyperactivity disorder (ADHD), Tourette syndrome, post-traumatic stress disorder (PTSD), and psychosis but concluded that the evidence of a positive effect was sparse compared with placebo.

Lead author Professor Louisa Degenhardt, of the National Drug and Alcohol Research Centre (NDARC) at UNSW Sydney, Australia, said: "Our findings have important implications in countries where cannabis and cannabinoids are being made available for medical use".

Medicinal cannabis has been said to be able to alleviate and help those living with mental health issues but research published yesterday says that prescribing such drugs could be more harmful than helpful to such individuals. But no reviews have considered the varying effects of the different types of cannabinoids or their safety, and the only studies into long-term effects were conducted on individuals using cannabis for recreational use.

There was, they said, "low-quality evidence" that THC, one of the derivatives of cannabis, could be helpful to people with multiple sclerosis or chronic pain who were also suffering from anxiety. Some studies showed improvement in anxiety symptoms, but it was unclear if that effect was due to improvements in the primary condition. But it made people with psychosis worse. - Safety risks - There are safety concerns as well.

Scientists said this is due to a lack of evidence for their effectiveness, and because of the known risks of cannabinoids.

This, they say, is due to a large body of evidence indicating that non-medicinal cannabis use can increase the occurrence of depression, anxiety, and psychotic symptoms.

'Miracle on ice' star Pavelich incompetent to stand trial in beatdown
But a Minnesota judge said Pavelich "needs some assistance" comprehending the proceedings, referring to a psychologist's report. According to the criminal complaint, Pavelich had grown angry, accusing Miller of "spiking his beer ".

Also, getting the drugs via the illicit market "carries risk of prosecution as well as unknown product content, quality and safety", added Tom Freeman, of the Addiction and Mental Health Group at the University of Bath.

Deepak Cyril D'Souza of Yale University School of Medicine in CT said cannabinoids should first be tested in randomized controlled trials and subjected to the same regulatory approval process as other prescription medications if they were to be used in the treatment of psychiatric disorders.

David Nutt, Head of the Centre for Neuropsychopharmacology at Imperial College London, said theLancetstudy somewhat missed the point.

The examine discovered that after power non-cancer ache, psychological well being is without doubt one of the most typical causes for utilizing medicinal cannabinoids.

Nicola Black et al. "For cannabinoids to be used in the treatment of psychiatric disorders they should be tested in RCTs and subjected to the same regulatory approval process as other prescription medications".

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.